Blueprint for Breakthroughs is a LinkedIn newsletter published by Adrienne B. Mendoza, MHA, SVP BioBridge Global and Chief Operating Officer (COO), BBG Advanced Therapies Originally
BBG Advanced Therapies was recently highlighted in a GlobalData feature examining the emerging role of extracellular vesicles (EVs) in regenerative medicine and targeted drug delivery.
Blueprint for Breakthroughs is a LinkedIn newsletter published by Adrienne B. Mendoza, MHA, SVP BioBridge Global and Chief Operating Officer (COO), BBG Advanced Therapies Originally
Blueprint for Breakthroughs is a LinkedIn newsletter published by Adrienne B. Mendoza, MHA, SVP BioBridge Global and Chief Operating Officer (COO), BBG Advanced Therapies Originally
Heather Munoz discusses how blood center infrastructure and flexible collection models are supporting the continued growth of cell and gene therapy. Heather Munoz, principal, global
Building on the success of the 2025 Red & White Ball, the goal for this year’s ball will be “funding the mission of BioBridge Global,” Foundation Executive Director Jay Podjenski shared with members of the board at its first meeting of 2026.
Program milestone highlights lifesaving impact of civilian prehospital whole blood in San Antonio and beyond On Thursday, Jan. 29, South Texas Blood & Tissue celebrated
Blueprint for Breakthroughs is a LinkedIn newsletter published by Adrienne B. Mendoza, MHA, SVP BioBridge Global and Chief Operating Officer (COO), BBG Advanced Therapies Originally
Blueprint for Breakthroughs is a LinkedIn newsletter published by Adrienne B. Mendoza, MHA, SVP BioBridge Global and Chief Operating Officer (COO), BBG Advanced Therapies Originally
Before sunrise on MLK Day, more than 50 BioBridge Global staff members gathered in downtown San Antonio to take part in the city’s annual MLK
Blueprint for Breakthroughs is a LinkedIn newsletter published by Adrienne B. Mendoza, MHA, SVP BioBridge Global and Chief Operating Officer (COO), BBG Advanced Therapies Originally
Potency assays are a cornerstone of effective cell therapies, but they can also be a source of delay during development. We spoke with Scott Jones,